Management of loss of response to anti-TNF drugs: Change the dose or change the drug?

Journal of Crohn's and Colitis

Volumn 2, Issue 4, 2008, Pages 348-351

  Van Assche, Gert ^a   Vermeire, Séverine ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Adalimumab; Anti TNF agents; Certolizumab; Crohn's disease; Infliximab; Tachyphylaxis; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CLINICAL TRIAL; CROHN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 56449116537     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2008.05.011     Document Type: Note

References (23)

1. Hanauer S., Lukáš M., MacIntosh D., Rutgeerts P., Sandborn W., and Pollack P. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology 130 (2006) 323-333
2. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
3. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26 week placebo-controlled phase III study (PRECiSe 1). Gastroenterology 130 (2006) A-107
4. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007) 239-250
5. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 3 (2005 Sep) 807-818
6. Sandborn W.J., Feagan B.G., Stoinov S., et al., PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007) 228-238
7. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
8. Hwang W.Y.K., and Foote J. Immunogenicity of engineered antibodies. Methods 36 (2005) 3-10
9. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 63 3 (2006) 433-442
10. Colombel J., Sandborn W.J., Rutgeerts P., et al. Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
11. Sandborn W.J., Hanauer S.B., Rutgeerts P.J., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56 (2007) 1232-1239
12. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
13. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66 (2007) 921-926
14. St Clair E.W., Wagner C.L., Fasanmade A.A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1451-1459
15. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134 (2008) 1861-1868
16. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
17. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 9 (Feb 26 2004) 876-885
18. Farrell R.J., Alsahli M., Jeen Y.T., Falchuk K.R., Peppercorn M.A., and Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124 (2003) 917-924
19. Hanauer S.B., Wagner C.L., and Bala M. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 542-553
20. Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., and Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56 9 (Sep 2007) 1226-1231
21. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 440 Crohn's disease patients: results from a single center cohort. Gastroenterology 132 (2007) A-14520
22. Maser E.A., Villela R., Silverberg M.S., and Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 1248-1254
23. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. Ann Intern Med 146 (2007) 829-838